Jevtana cabazitaxel regulatory update
The German Institute for Quality and Efficiency in Health Care (IQWiG) said Jevtana cabazitaxel from Sanofi provides significant additional benefit over palliative care and best supportive care for patients 65 years or older with castration-resistant prostate cancer (CRPC) for whom docetaxel is no longer an option. The agency also said there is evidence of potential additional benefit over the comparators for CRPC patients under 65 who can no longer be treated with docetaxel.
Palliative treatment consists of dexamethasone, prednisone, prednisolone or methylprednisolone. IQWiG determined that Jevtana plus prednisone or prednisolone showed no additional benefit over docetaxel for CRPC patients who could still receive docetaxel treatment because the agency did not have sufficient data. ...